Companies
Israeli Oncologists Show Point-of-Care CAR T Cells Have Comparable Efficacy to Yescarta, Kymriah
Premium
Lymphoma patients better tolerated the CAR T-cell therapy manufactured on-site at the Sheba Medical Center than they did the commercially available options.
In particular, patients who had fewer than 10 annual vaso-occlusive events before the gene therapy were more likely to have none after treatment.
Perspective: The Future of Precision Medicine Depends on Collaboration Across the Healthcare Landscape
Success in this field demands investment in infrastructure, expanded education for healthcare providers, and improved access to genetic services.
HER2 Biomarker Evolving as Enhertu Shows Activity in Breast Cancers With Ultralow Expression
Premium
The new HER2-low category is exposing the limitations of IHC testing, challenging pathologists, and has oncologists revisiting patients' old test results.
Denali Therapeutics Doses First LRRK2 Parkinson's Patient in Phase IIa Trial
BIIB122, previously known as DNL151, is a small molecule designed to inhibit LRRK2, mutations in which are the most common cause of inherited Parkinson's.